Gabriel Lachance, Karine Robitaille, Jalal Laaraj, Nikunj Gevariya, Thibault V Varin, Andrei Feldiorean, Fanny Gaignier, Isabelle Bourdeau Julien, Hui Wen Xu, Tarek Hallal, Jean-François Pelletier, Sidki Bouslama, Nadia Boufaied, Nicolas Derome, Alain Bergeron, Leigh Ellis, Ciriaco A Piccirillo, Frédéric Raymond, Yves Fradet, David P Labbé, André Marette, Vincent Fradet
The gut microbiota modulates response to hormonal treatments in prostate cancer (PCa) patients, but whether it influences PCa progression remains unknown. Here, we show a reduction in fecal microbiota alpha-diversity correlating with increase tumour burden in two distinct groups of hormonotherapy naïve PCa patients and three murine PCa models. Fecal microbiota transplantation (FMT) from patients with high PCa volume is sufficient to stimulate the growth of mouse PCa revealing the existence of a gut microbiome-cancer crosstalk...
April 23, 2024: Nature Communications